EICHORCondition: Kidney Transplantation in Highly Sensitized Patients · Sponsor: Hansa Biopharma AB
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (UAB) Hospital | Birmingham, Alabama, United States | — |
| Banner Health - University Medical Center - Phoenix | Phoenix, Arizona, United States | — |
| Mayo Clinic Phoenix | Phoenix, Arizona, United States | — |
| Keck Hospital of University of Southern California (USC) | Los Angeles, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
| Sutter Health - California Pacific Medical Center | San Francisco, California, United States | — |
| University of California San Francisco (UCSF) Medical Center | San Francisco, California, United States | — |
| Georgetown Transplant Institute | Washington D.C., District of Columbia, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | — |
| John Hopkins Hospital | Baltimore, Maryland, United States | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04935177